2021
Loss of hepatic miR-33 improves metabolic homeostasis and liver function without altering body weight or atherosclerosis
Price NL, Zhang X, Fernández-Tussy P, Singh AK, Burnap SA, Rotllan N, Goedeke L, Sun J, Canfrán-Duque A, Aryal B, Mayr M, Suárez Y, Fernández-Hernando C. Loss of hepatic miR-33 improves metabolic homeostasis and liver function without altering body weight or atherosclerosis. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2006478118. PMID: 33495342, PMCID: PMC7865172, DOI: 10.1073/pnas.2006478118.Peer-Reviewed Original ResearchConceptsMiR-33 deficiencyHDL-C levelsMiR-33Body weightAtherosclerotic plaque sizeAtherosclerotic plaque burdenDevelopment of fibrosisCholesterol transport capacityCholesterol transporter ABCA1High-density lipoprotein biogenesisSREBP2 transcription factorKnockout mouse modelConditional knockout mouse modelPlaque burdenCardiometabolic diseasesChow dietLiver functionMetabolic dysfunctionHDL metabolismHyperlipidemic conditionsMouse modelGlucose homeostasisCholesterol effluxLipid metabolismObesity
2010
microRNAs, Plasma Lipids, and Cardiovascular Disease
Dávalos A, Fernández-Hernando C. microRNAs, Plasma Lipids, and Cardiovascular Disease. Current Cardiovascular Risk Reports 2010, 5: 10-17. DOI: 10.1007/s12170-010-0145-1.Peer-Reviewed Original ResearchCardiovascular diseaseShort non-coding RNAsPost-transcriptional repressionHigh-density lipoprotein biogenesisMiR-33Non-coding RNAsTotal cholesterol levelsCassette transporter A1Expression of ATPMiR-122 expressionAberrant regulationGene expressionLipoprotein biogenesisDyslipidemic patientsLipid homeostasisMetabolic syndromePlasma lipidsCholesterol levelsLeading causeLipoprotein metabolismABCG1 transportersCholesterol effluxCholesterol metabolismPathologic processesMultifactorial disorder